Market Cap 6.75B
Revenue (ttm) 4.07B
Net Income (ttm) 560.12M
EPS (ttm) N/A
PE Ratio 6.55
Forward PE 53.50
Profit Margin 13.77%
Debt to Equity Ratio 1.29
Volume 637,500
Avg Vol 1,297,786
Day's Range N/A - N/A
Shares Out 61.65M
Stochastic %K 49%
Beta 0.33
Analysts Strong Sell
Price Target $181.67

Latest News on JAZZ

Jazz Pharmaceuticals: One Step Forward, One Back

May 21, 2025, 4:58 AM EDT - 15 days ago

Jazz Pharmaceuticals: One Step Forward, One Back


Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr 21, 2025, 4:05 PM EDT - 6 weeks ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix


Jazz Pharmaceuticals to buy Chimerix for $935 million

Mar 5, 2025, 7:14 AM EST - 3 months ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

CMRX


Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 9:20 PM EST - 3 months ago

Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 4 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT ONC XBI ZYME


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 5 months ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI


Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 23, 2024, 12:53 PM EST - 5 months ago

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025


Jazz Pharmaceuticals Announces CEO Succession Plan

Dec 16, 2024, 4:05 PM EST - 6 months ago

Jazz Pharmaceuticals Announces CEO Succession Plan